Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“2025 is “ADC year”.
Two practice-changing ADC phase 3 trials announced to be positive.
At least 6 more may read out this year, likely leading to further changes in the treatment of breast cancer. Exciting times.”
